APA (7th ed.) Citation

Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., . . . Rayner, C. K. (2016). The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes (New York, N.Y.), 65(1), 269-275. https://doi.org/10.2337/db15-0893

Chicago Style (17th ed.) Citation

Thazhath, Sony S., et al. "The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial." Diabetes (New York, N.Y.) 65, no. 1 (2016): 269-275. https://doi.org/10.2337/db15-0893.

MLA (9th ed.) Citation

Thazhath, Sony S., et al. "The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial." Diabetes (New York, N.Y.), vol. 65, no. 1, 2016, pp. 269-275, https://doi.org/10.2337/db15-0893.